{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:51:20Z","timestamp":1793404280347,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-EU-131-4502"],"award-info":[{"award-number":["IN-EU-131-4502"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-EU-131-4502"],"award-info":[{"award-number":["IN-EU-131-4502"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-EU-131-4502"],"award-info":[{"award-number":["IN-EU-131-4502"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-EU-131-4502"],"award-info":[{"award-number":["IN-EU-131-4502"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The heterogeneity of clinical responses to antifungals in aspergillosis is partially understood. We hypothesized that besides direct antifungal effects, these discrepancies may be related to different immunomodulatory profiles. Human THP-1 monocytes were coincubated in vitro with\n                    <jats:italic>Aspergillus fumigatus<\/jats:italic>\n                    and variable concentrations of voriconazole (0.5, 1 and 2\u00a0mg\/l), caspofungin (1 and 2\u00a0mg\/l), amphotericin B deoxycholate (0.25, 0.5 and 1\u00a0mg\/l) and liposomal amphotericin B (1, 2 and 3\u00a0mg\/l). After 6\u00a0h of coincubation, total cellular RNA was extracted, converted into cDNA, and transcription of 84 genes involved in antifungal immunity was measured through RT-qPCR. The presence of\n                    <jats:italic>A. fumigatus<\/jats:italic>\n                    was the main driver of the global immune-related transcriptomic response\n                    <jats:italic>.<\/jats:italic>\n                    After\n                    <jats:italic>Aspergillus<\/jats:italic>\n                    infection, thirty genes were upregulated, while 19 genes were downregulated. Discrepancies across antifungals were also evident; voriconazole-containing conditions showed similar reaction to natural infection, while the use of liposomal Amphotericin B significantly decreased the inflammatory response. Chemokines (notably CCL20 and CXCL2) and pro-inflammatory cytokines (IL1A, IL1B, IL23, G-CSF) exhibited the most pronounced differences across antifungals. Pattern recognition receptors and adaptor protein transcription were minimally affected. Protein\u2013protein-interaction network analysis showed that IL23A played a dominant role in upregulated genes. Pathway enrichment analysis indicated that cytokine-cytokine receptor integration, TNF signaling pathways and Toll-like receptor pathways were highly involved. This exploratory study confirms the heterogeneous immunomodulatory role of antifungals. Overall, voriconazole appears to maintain an early pro-inflammatory response seen in natural infection. Assessment of immunomodulatory response with clinical response may provide a better rationale for differences observed across antifungals.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-08738-4","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T07:04:45Z","timestamp":1647500685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antifungals influence the immune-related transcriptomic landscape of human monocytes after Aspergillus fumigatus infection"],"prefix":"10.1038","volume":"12","author":[{"given":"Beno\u00eet","family":"Henry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Klement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajiha","family":"Gohir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"8738_CR1","doi-asserted-by":"publisher","first-page":"e00140","DOI":"10.1128\/CMR.00140-18","volume":"33","author":"J-P Latg\u00e9","year":"2019","unstructured":"Latg\u00e9, J.-P. & Chamilos, G. Aspergillus fumigatus and Aspergillosis in 2019. Clin. Microbiol. Rev. 33, e00140 (2019).","journal-title":"Clin. Microbiol. Rev."},{"key":"8738_CR2","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1126\/science.aaa6097","volume":"347","author":"DW Denning","year":"2015","unstructured":"Denning, D. W. & Bromley, M. J. Infectious disease. How to bolster the antifungal pipeline. Science 347, 1414\u20131416 (2015).","journal-title":"Science"},{"key":"8738_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s10096-017-2922-y","volume":"36","author":"SF Dufresne","year":"2017","unstructured":"Dufresne, S. F., Cole, D. C., Denning, D. W. & Sheppard, D. C. Serious fungal infections in Canada. Eur. J. Clin. Microbiol. Infect. Dis. 36, 987\u2013992 (2017).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"8738_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/cid\/ciu337","volume":"59","author":"JF Camargo","year":"2014","unstructured":"Camargo, J. F. & Husain, S. Immune correlates of protection in human invasive aspergillosis. Clin. Infect. Dis. 59, 569\u2013577 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"8738_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson, T. F. et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases Society of America. Clin. Infect. Dis. 63, e1\u2013e60 (2016).","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 1","key":"8738_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann, A. J. et al. Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin. Microbiol. Infect. 24(Suppl 1), e1\u2013e38 (2018).","journal-title":"Clin. Microbiol. Infect."},{"key":"8738_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"8","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht, R. et al. Voriconazole versus Amphotericin B for primary therapy of invasive aspergillosis. New Engl. J. Med. 8, 408\u2013415 (2002).","journal-title":"New Engl. J. Med."},{"key":"8738_CR8","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens, J. A. et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial. Lancet 387, 760\u2013769 (2016).","journal-title":"Lancet"},{"key":"8738_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","volume":"397","author":"JA Maertens","year":"2021","unstructured":"Maertens, J. A. et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: A phase 3, randomised, controlled, non-inferiority trial. Lancet 397, 499\u2013509 (2021).","journal-title":"Lancet"},{"key":"8738_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/M13-2508","volume":"162","author":"KA Marr","year":"2015","unstructured":"Marr, K. A. et al. Combination antifungal therapy for invasive aspergillosis: A randomized trial. Ann. Intern. Med. 162, 81\u201389 (2015).","journal-title":"Ann. Intern. Med."},{"key":"8738_CR11","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1128\/AAC.01095-06","volume":"51","author":"M Simitsopoulou","year":"2007","unstructured":"Simitsopoulou, M. et al. Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus. Antimicrob. Agents Chemother. 51, 1048\u20131054 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8738_CR12","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: Protein\u2013protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607\u2013D613 (2019).","journal-title":"Nucleic Acids Res."},{"key":"8738_CR13","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"8738_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"8738_CR15","first-page":"D498","volume":"48","author":"B Jassal","year":"2020","unstructured":"Jassal, B. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 48, D498\u2013D503 (2020).","journal-title":"Nucleic Acids Res."},{"key":"8738_CR16","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1182\/blood-2005-04-1660","volume":"107","author":"O Beck","year":"2006","unstructured":"Beck, O. et al. Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood 107, 2562\u20132569 (2006).","journal-title":"Blood"},{"key":"8738_CR17","doi-asserted-by":"publisher","first-page":"e10008","DOI":"10.1371\/journal.pone.0010008","volume":"5","author":"N Sa\u00efd-Sadier","year":"2010","unstructured":"Sa\u00efd-Sadier, N., Padilla, E., Langsley, G. & Ojcius, D. M. Aspergillus fumigatus stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase. PLoS ONE 5, e10008 (2010).","journal-title":"PLoS ONE"},{"key":"8738_CR18","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1128\/AAC.01018-07","volume":"52","author":"M Simitsopoulou","year":"2008","unstructured":"Simitsopoulou, M. et al. Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: Differential role of Toll-like receptors. Antimicrob. Agents Chemother. 52, 3301\u20133306 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8738_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3109\/13693786.2010.510539","volume":"49","author":"M Simitsopoulou","year":"2011","unstructured":"Simitsopoulou, M., Roilides, E., Georgiadou, E., Paliogianni, F. & Walsh, T. J. Differential transcriptional profiles induced by amphotericin B formulations on human monocytes during response to hyphae of Aspergillus fumigatus. Med. Mycol. 49, 176\u2013185 (2011).","journal-title":"Med. Mycol."},{"key":"8738_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1179\/joc.2008.20.3.327","volume":"20","author":"LW Turtinen","year":"2008","unstructured":"Turtinen, L. W., Croswell, A. & Obr, A. Microarray analysis of amphotericin B-treated THP-1 monocytic cells identifies unique gene expression profiles among lipid and non-lipid drug formulations. J. Chemother. 20, 327\u2013335 (2008).","journal-title":"J. Chemother."},{"key":"8738_CR21","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1128\/AAC.49.4.1617-1621.2005","volume":"49","author":"RR Razonable","year":"2005","unstructured":"Razonable, R. R. et al. Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2. Antimicrob. Agents Chemother. 49, 1617\u20131621 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8738_CR22","doi-asserted-by":"publisher","first-page":"e01993","DOI":"10.1128\/AAC.01993-18","volume":"63","author":"S Schmidt","year":"2019","unstructured":"Schmidt, S., Schubert, R., Tramsen, L. & Lehrnbecher, T. Impact of antifungal compounds on viability and anti-Aspergillus activity of human natural killer cells. Antimicrob. Agents Chemother. 63, e01993-e2018 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"8738_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ijc.2910260208","volume":"26","author":"S Tsuchiya","year":"1980","unstructured":"Tsuchiya, S. et al. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer 26, 171\u2013176 (1980).","journal-title":"Int. J. Cancer"},{"key":"8738_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3109\/13693780903148346","volume":"48","author":"R Ben-Ami","year":"2010","unstructured":"Ben-Ami, R., Lamaris, G. A., Lewis, R. E. & Kontoyiannis, D. P. Interstrain variability in the virulence of Aspergillus fumigatus and Aspergillus terreus in a Toll-deficient Drosophila fly model of invasive aspergillosis. Med. Mycol. 48, 310\u2013317 (2010).","journal-title":"Med. Mycol."},{"key":"8738_CR25","doi-asserted-by":"publisher","first-page":"108389","DOI":"10.1016\/j.celrep.2020.108389","volume":"33","author":"B Seelbinder","year":"2020","unstructured":"Seelbinder, B. et al. Triple RNA-Seq reveals synergy in a human virus-fungus co-infection model. Cell Rep. 33, 108389 (2020).","journal-title":"Cell Rep."},{"key":"8738_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.intimp.2014.08.002","volume":"23","author":"W Chanput","year":"2014","unstructured":"Chanput, W., Mes, J. J. & Wichers, H. J. THP-1 cell line: An in vitro cell model for immune modulation approach. Int. Immunopharmacol. 23, 37\u201345 (2014).","journal-title":"Int. Immunopharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08738-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08738-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08738-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T19:06:24Z","timestamp":1669316784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08738-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8738"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-08738-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"19 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4581"}}